Guido Oelkers, Sobi CEO
September 3, 2021 09:11 AM EDTUpdated 10:59 AM
Deals

Pri­vate eq­ui­ty, sov­er­eign wealth fund al­ly on an $8B buy­out aimed at tak­ing rare dis­ease play­er pri­vate

John Carroll

Editor & Founder

A pri­vate eq­ui­ty group has joined hands with a sov­er­eign wealth fund out of Sin­ga­pore to strike a deal to buy Swedish Or­phan Biovit­rum …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Ap­plied Ther­a­peu­tic­s' rare dis­ease drug gets a CRL

PTC re­ports Phase 2 ALS fail, sells pri­or­i­ty re­view vouch­er for $150M

FDA is look­ing in­to hema­tol­ogy risks af­ter pa­tients take Blue­bird's Skysona gene ther­a­py

To lead NIH, Trump taps Stan­ford aca­d­e­m­ic and pan­dem­ic re­sponse crit­ic Jay Bhat­tacharya

No­var­tis to cut 139 jobs in NJ as part of com­mer­cial re­fo­cus

Nor­bert Bischof­berg­er's time as Kro­nos CEO ends as biotech seeks new life

A service from the Financial Times